Drug General Information
Drug ID
D07CNY
Former ID
DIB016518
Drug Name
Instiladrin
Indication Bladder cancer [ICD9: 188; ICD10:C67] Phase 2 [524056]
Company
Fkd therapies
Target and Pathway
Target(s) Interferon alpha 2 ligand Target Info Modulator [524056]
KEGG Pathway Cytokine-cytokine receptor interaction
Regulation of autophagy
PI3K-Akt signaling pathway
Toll-like receptor signaling pathway
RIG-I-like receptor signaling pathway
Cytosolic DNA-sensing pathway
Jak-STAT signaling pathway
Natural killer cell mediated cytotoxicity
Tuberculosis
Hepatitis C
Hepatitis B
Measles
Influenza A
Herpes simplex infection
Autoimmune thyroid disease
NetPath Pathway IL2 Signaling Pathway
Pathway Interaction Database Downstream signaling in na&#xef
Reactome Interferon alpha/beta signaling
Regulation of IFNA signaling
TRAF6 mediated IRF7 activation
Factors involved in megakaryocyte development and platelet production
WikiPathways Toll-like receptor signaling pathway
Type II interferon signaling (IFNG)
Interferon alpha/beta signaling
Regulation of toll-like receptor signaling pathway
References
Ref 524056ClinicalTrials.gov (NCT01687244) Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer. U.S. National Institutes of Health.
Ref 524056ClinicalTrials.gov (NCT01687244) Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.